Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis
New England Journal of Medicine · 2025
DOI: 10.1056/nejmoa2415985 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2025. Verfasst von Jiwon Oh und 13 weiteren Autor:innen. Beteiligte Einrichtung: St. Michael's Hospital, University of Toronto, Toronto. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Multiple Sclerosis, Relapsing-Remitting, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Sanofi.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- St. Michael's Hospital, University of Toronto, Toronto.
- McGill University, Montreal.
- NeuroRx Research, Montreal.
- Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco.
- Department of Neurology, UMass Chan Medical School, Worcester, MA.
- Department of Neurology, National Cancer Center, Goyang, South Korea.
ORCID-Profile: Jiwon Oh, Maria Pia Sormani
Förderung
- Sanofi
Zitieren
APA
Oh, J., Arnold, D. L., Cree, B. A. C., Ionete, C., Kim, H. J., Sormani, M. P., Syed, S., Chen, Y., Maxwell, C. R., Benoit, P., Turner, T. J., Wallstroem, E., Wiendl, H., & Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group (2025). Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2415985
Vancouver
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, et al. Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. New England Journal of Medicine. 2025. doi:10.1056/nejmoa2415985
BibTeX
@article{Oh2025,
author = {Oh, Jiwon and Arnold, Douglas L and Cree, Bruce A C and Ionete, Carolina and Kim, Ho Jin and Sormani, Maria Pia and Syed, Sana and Chen, Yixin and Maxwell, Christina R and Benoit, Patrick and Turner, Timothy J and Wallstroem, Erik and Wiendl, Heinz and Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group, Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group},
title = {Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis},
journal = {New England Journal of Medicine},
year = {2025},
doi = {10.1056/nejmoa2415985}
}
EUVIMED